<h2 id="what-is-neostigmine">What is Neostigmine?</h2>
<ul>
  <li>Neostigmine is a cholinesterase inhibitor generally used to reverse non-depolarizing muscle relaxants like <a href="Rocuronium">Rocuronium</a>.</li>
</ul>
<h2 id="mechanism-of-action--pharmacokinetics-">Mechanism of Action &amp; Pharmacokinetics <sup id="fnref:1" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup><sup id="fnref:2" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<ul>
  <li><strong>Mechanism of Action:</strong> Neostigmine inhibits acetylcholinesterase, preventing the breakdown of acetylcholine =&gt; Leads to enhanced stimulation of nicotinic and muscarinic receptors.</li>
  <li><strong>Secondary Effects:</strong> Leads to muscarinic receptor stimulation, which can lead to bradycardia, increased secretions, and bronchospasm. <a href="Glycopyrrolate">Glycopyrrolate</a> can reduce these effects</li>
</ul>
<h2 id="pharmacodynamics-">Pharmacodynamics <sup id="fnref:1:1" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup><sup id="fnref:2:1" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<h3 id="cardiovascular">Cardiovascular</h3>
<ul>
  <li>Bradycardia due to its stimulation of the parasympathetic nervous system.</li>
</ul>
<h3 id="respiratory">Respiratory</h3>
<ul>
  <li>Can cause bronchospasm due to stimulation of muscarinic receptors in the bronchial smooth muscles.</li>
</ul>
<h2 id="indications-">Indications <sup id="fnref:1:2" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup><sup id="fnref:2:2" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<h3 id="reversal-of-neuromuscular-blockade">Reversal of Neuromuscular Blockade</h3>
<ul>
  <li>Used to reverse the effects of non-depolarizing neuromuscular blocking agents (NDMRs) like <a href="Rocuronium">Rocuronium</a> and vecuronium.</li>
  <li>Works by increasing the concentration of acetylcholine at the neuromuscular junction, outcompeting the NDMRs</li>
</ul>
<h2 id="dosing-">Dosing <sup id="fnref:1:3" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup><sup id="fnref:2:3" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<ul>
  <li><strong>Reversal of NDMR:</strong> 0.03 - 0.07 mg/kg IV, usually administered with glycopyrrolate to mitigate muscarinic side effects.</li>
  <li>Due to the side effects of neostigmine, often the dose does not exceed 3mg.</li>
  <li>
    <table>
      <tbody>
        <tr>
          <td>The ratio of neostigmine to [[../Anesthesia/Body Weight Dosing/Glycopyrrolate</td>
          <td>Glycopyrrolate]] is 5:1.</td>
        </tr>
      </tbody>
    </table>
  </li>
</ul>
<h2 id="complications--">Complications  <sup id="fnref:1:4" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup><sup id="fnref:2:4" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<ul>
  <li><strong>Bradycardia:</strong> Often requires co-administration of an anticholinergic agent like glycopyrrolate.</li>
  <li><strong>Bronchospasm:</strong> Due to stimulation of muscarinic receptors.</li>
  <li><strong>Gastrointestinal:</strong> Nausea, vomiting, and increased gastrointestinal motility.</li>
</ul>
<h2 id="references">References</h2>
<div class="footnotes" role="doc-endnotes">
  <ol>
    <li id="fn:1" role="doc-endnote">
      <p>Sullivan, P. (2012). <em>Ottawa Anesthesia Primer.</em> Echo Book Publishing. <a href="#fnref:1" class="reversefootnote" role="doc-backlink">&#8617;</a> <a href="#fnref:1:1" class="reversefootnote" role="doc-backlink">&#8617;<sup>2</sup></a> <a href="#fnref:1:2" class="reversefootnote" role="doc-backlink">&#8617;<sup>3</sup></a> <a href="#fnref:1:3" class="reversefootnote" role="doc-backlink">&#8617;<sup>4</sup></a> <a href="#fnref:1:4" class="reversefootnote" role="doc-backlink">&#8617;<sup>5</sup></a></p>
    </li>
    <li id="fn:2" role="doc-endnote">
      <p>Shafer SL, Rathmell JP, Flood P. (2015). <em>Stoelting’s Pharmacology and Physiology in Anesthetic Practice.</em> Fifth edition. Philadelphia: Wolters Kluwer Health. <a href="#fnref:2" class="reversefootnote" role="doc-backlink">&#8617;</a> <a href="#fnref:2:1" class="reversefootnote" role="doc-backlink">&#8617;<sup>2</sup></a> <a href="#fnref:2:2" class="reversefootnote" role="doc-backlink">&#8617;<sup>3</sup></a> <a href="#fnref:2:3" class="reversefootnote" role="doc-backlink">&#8617;<sup>4</sup></a> <a href="#fnref:2:4" class="reversefootnote" role="doc-backlink">&#8617;<sup>5</sup></a></p>
    </li>
  </ol>
</div>